Thoratec's (THOR) New CEO Seen as Positive, Says Wells Fargo (Earlier)
Get Alerts THOR Hot Sheet
Rating Summary:
8 Buy, 16 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 12 | New: 13
Join SI Premium – FREE
Wells Fargo earlier maintained an Market Perform rating on Thoratec (NASDAQ: THOR). Comments follow news D. Keith Grossman has been appointed President and Chief Executive Officer, effective immediately. Mr. Grossman succeeds Gary F. Burbach, who has stepped down. In the view of analyst Larry Biegelsen, the news wasn't a complete surprise.
The analyst went on to say he thinks investors will focus on Grossman's track record at Conceptus, which was turned around and eventually sold to Bayer. In Biegelsen's view, Thoratec could be an attractive M&A candidate once investors have clarity on its HeartMate III device.
For an analyst ratings summary and ratings history on Thoratec click here. For more ratings news on Thoratec click here.
Shares of Thoratec closed at $26.14 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- ByteDance Prefers TikTok Shutdown in US if Legal Options Fail - Reuters
- Sage Therapeutics (SAGE) PT Lowered to $18 at Truist Securities
- Mr. Cooper Group (COOP) Appoints Ranjit Bhattacharjee as CIO and President, Kevin Barker as SVP of Corporate Finance
Create E-mail Alert Related Categories
Analyst Comments, Management Changes, RumorsRelated Entities
Wells FargoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!